NASDAQ · Financial Statements

Vistagen Therapeutics, Inc. (VTGN) Revenue, Earnings & Financial Statements

$0.19 NASDAQ: VTGN Market Cap $8.34M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Vistagen Therapeutics, Inc. most recently reported annual revenue of $1.0M, a net loss of $70.0M. Revenue was roughly flat over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Vistagen Therapeutics, Inc.: Revenue rose from $1.0M in 2017 to $1.0M in 2026, a change of +0.0% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -819.9% to -5683.7%, a shift of -4863.8 percentage points; the most recent year shows a net loss of $70.0M.

Income Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Revenue$1.0M$0$0$0$1.0M$1.0M$0$1.0M$0$1.0M
Operating Expenses$11.0M$14.0M$25.0M$20.0M$19.0M$49.0M$59.0M$34.0M$56.0M$73.0M
Operating Profit−$10.0M−$14.0M−$25.0M−$20.0M−$18.0M−$48.0M−$59.0M−$33.0M−$56.0M−$72.0M
Operating Margin-819.9%———-1646.1%-4308.7%26109.3%-3103.5%-11517.1%-5683.7%
Other Income$0$0$0−$1.0M$0$0$0$4.0M$5.0M$2.0M
Interest$0$0$0$0$0$0$0$0$0$0
Depreciation$0$0$0$0$0$1.0M$1.0M$1.0M$1.0M$1.0M
Profit Before Tax−$10.0M−$14.0M−$25.0M−$21.0M−$18.0M−$48.0M−$59.0M−$29.0M−$51.0M−$70.0M
Tax rate (%)-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%
Net Profit−$10.0M−$14.0M−$25.0M−$21.0M−$18.0M−$48.0M−$59.0M−$29.0M−$51.0M−$70.0M
EPS−$40.85−$30.98−$25.83−$14.21−$14.74−$7.38−$8.51−$1.52−$1.67−$1.83

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$0$0$0$0$0$1.0M$0
Operating Expenses$8.0M$12.0M$12.0M$14.0M$15.0M$14.0M$16.0M$20.0M$20.0M$17.0M$15.0M$11.0M
Operating Profit−$8.0M−$11.0M−$12.0M−$14.0M−$15.0M−$14.0M−$16.0M−$20.0M−$20.0M−$17.0M−$13.0M−$11.0M
Operating Margin-1916.4%-5757.2%-14441.7%-7774.3%-6461.5%96633.3%-6477.1%-7772.5%-6450.8%-3595.1%-904.3%-7925.4%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$6.0M−$10.0M−$11.0M−$13.0M−$14.0M−$14.0M−$15.0M−$19.0M−$19.0M−$16.0M−$13.0M−$11.0M
Tax rate (%)0.0%-0.0%0.0%-0.1%0.0%0.0%0.0%0.0%0.0%-0.0%0.0%0.0%
Net Profit−$6.0M−$10.0M−$11.0M−$13.0M−$14.0M−$14.0M−$15.0M−$19.0M−$19.0M−$16.0M−$13.0M−$11.0M
EPS−$0.22−$0.35−$0.35−$0.42−$0.46−$0.44−$0.47−$0.54−$0.45−$0.41−$0.30−$0.24

Over the 10 years reported for Vistagen Therapeutics, Inc., cash stood at $31.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.62 times.

Balance Sheet — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Total Assets$4.0M$11.0M$14.0M$6.0M$108.0M$75.0M$21.0M$124.0M$84.0M$49.0M
Current Assets$3.0M$11.0M$14.0M$2.0M$104.0M$71.0M$18.0M$121.0M$82.0M$47.0M
Cash$3.0M$10.0M$13.0M$1.0M$103.0M$68.0M$17.0M$119.0M$67.0M$31.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$3.0M$1.0M$0$0$0
Fixed Assets$0$0$0$4.0M$4.0M$3.0M$3.0M$2.0M$2.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$13.0M$15.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$3.0M$4.0M$7.0M$12.0M$16.0M$10.0M$9.0M$9.0M$14.0M$13.0M
Current Liabilities$1.0M$1.0M$3.0M$3.0M$4.0M$6.0M$5.0M$5.0M$13.0M$13.0M
Borrowings$0$0$0$4.0M$4.0M$3.0M$3.0M$2.0M$2.0M$1.0M
Other Liabilities$3.0M$4.0M$7.0M$7.0M$13.0M$7.0M$6.0M$7.0M$12.0M$12.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$1.0M$7.0M$7.0M−$6.0M$92.0M$65.0M$12.0M$114.0M$70.0M$36.0M

For Vistagen Therapeutics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $67.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Operating Cash Flow−$7.0M−$9.0M−$15.0M−$16.0M−$12.0M−$45.0M−$50.0M−$26.0M−$42.0M−$66.0M
Investing Cash Flow−$240.0M−$2.0M−$174.0M$0−$1.0M$0−$1.0M$0−$13.0M−$1.0M
Financing Cash Flow$1.3B$1.0B$1.2B$1.0M$5.0M$951.0M$0$0$0$0
Net Cash Flow$2.0M$7.0M$3.0M−$12.0M$102.0M−$35.0M−$51.0M$103.0M−$52.0M−$36.0M
Free Cash Flow−$8.0M−$9.0M−$15.0M−$16.0M−$12.0M−$45.0M−$50.0M−$26.0M−$42.0M−$67.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.04
FCF Yield-757.06%
Quick Ratio2.64
Interest Coverage—
Return 1Y-95.26%
Return 3Y-94.34%
Return 5Y-99.71%

Vistagen Therapeutics, Inc. (VTGN) financials — frequently asked questions

What is Vistagen Therapeutics, Inc.'s annual revenue?

Vistagen Therapeutics, Inc. (VTGN) reported annual revenue of $1.0M in its most recent fiscal year.

What is Vistagen Therapeutics, Inc.'s net profit?

Vistagen Therapeutics, Inc. (VTGN) reported a net loss of $70.0M in its most recent fiscal year.

What is VTGN EV/EBITDA?

Vistagen Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.04.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
VTGN Overview VTGN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.